文章摘要
乳酸菌阴道胶囊联合重组人干扰素α-2b凝胶对宫颈高危型人乳头瘤病毒感染患者阴道微生态和炎症因子的影响
Lactobacillus Vagina Capsule Combined With Recombinant Human Interferon α-2b Gel on Vaginal Microecology and Inflammatory Factors in Patients With High-Risk Cervical Human Papillomavirus Infection*
投稿时间:2021-08-24  修订日期:2021-08-24
DOI:
中文关键词: 乳酸菌阴道胶囊  重组人干扰素α-2b凝胶  高危型人乳头瘤病毒感染  疗效  阴道微生态  炎症因子
英文关键词: Lactobacillus vaginal capsule  Recombinant human interferon α-2b gel  High-risk human papillomavirus infection  Efficacy  Vaginal microecology  Inflammatory factors
基金项目:上海市科委科研计划项目(18401904200)
作者单位邮编
金铭歆 上海中医药大学附属曙光医院 201203
摘要点击次数: 12
全文下载次数: 0
中文摘要:
      目的:探讨乳酸菌阴道胶囊联合重组人干扰素α-2b凝胶治疗宫颈高危型人乳头瘤病毒(HR-HPV)感染的疗效及对阴道微生态和炎症因子的影响。方法:应用随机数字表法将我院2019年3月~2021年3月期间收治的94例宫颈HR-HPV感染患者分为对照组(n=47)和研究组(n=47)。对照组患者接受重组人干扰素α-2b凝胶治疗,研究组在此基础上联合乳酸菌阴道胶囊治疗。观察两组治疗结束后的疗效、阴道微生态、炎症因子、HPV-DNA病毒载量、HPV-DNA转阴情况,观察两组的用药安全性。结果:研究组临床总有效率(89.36%)高于对照组(65.96%),差异有统计学意义(P<0.05)。研究组的阴道分泌物pH、Nugent评分则低于对照组,阴道微生态正常或恢复率高于对照组(P<0.05)。两组治疗结束后血清肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、C反应蛋白(CRP)水平较治疗前降低,且研究组低于对照组(P<0.05)。两组治疗结束后HPV-DNA病毒载量较治疗前降低,且研究组低于对照组(P<0.05),研究组的HPV-DNA转阴率高于对照组(P<0.05)。两组不良反应发生率对比无明显差异(P>0.05)。结论:宫颈HR-HPV感染患者在重组人干扰素α-2b凝胶治疗基础上联合乳酸菌阴道胶囊治疗,可促进阴道微生态恢复,有效控制HR-HPV感染,降低患者体内炎症因子水平,疗效可靠。
英文摘要:
      Objective:To investigate the efficacy of Lactobacillus vaginal capsule combined with recombinant human interferon α-2b gel in the treatment of high-risk cervical human papillomavirus (HR-HPV) infection and its effects on vaginal microecology and inflammatory factors. Methods: 94 patients with cervical HR-HPV infection who were treated in our hospital from March 2019 to March 2021 were randomly divided into control group (n=47) and study group (n=47) by the random number table method. The patients in the control group were treated with recombinant human interferon α-2b gel, and patients in the study group were combined with Lactobacillus vaginal capsule on this basis. The efficacy, vaginal microecology, inflammatory factors, HPV-DNA viral load and HPV-DNA negative conversion rate of the two groups after treatment were observed, and the drug safety of the two groups was observed. Results: The clinical total effective rate of the study group (89.36%) was higher than (65.96%) of the control group (P<0.05). The pH of vaginal secretion and Nugent score of the study group were lower than those of the control group, and the normal or recovery rates of vaginal Microecology were higher than those of the control group (P<0.05). After treatment, the serum levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and C-reactive protein (CRP) of the two groups were lower than those before treatment, and the study group was lower than the control group (P<0.05). After treatment, the HPV-DNA viral load of the two groups was lower than that before treatment, and the study group was lower than the control group (P<0.05). The HPV-DNA negative conversion rate of the study group was higher than that of the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion:Based on the treatment of recombinant human interferon α-2b gel combined with Lactobacillus vaginal capsule for patients with cervical HR-HPV infection, it can promote the recovery of vaginal microecology, effectively control HPV infection, reduce the level of inflammatory factors in patients, and the efficacy is reliable.
View Fulltext   查看/发表评论  下载PDF阅读器
关闭